HB7118, titled the Genomic Answers for Children’s Health Act of 2026, would amend the Medicaid statute to clarify that whole genome sequencing and whole exome sequencing are covered services for children with certain medical needs. The bill specifies that these tests may be covered when ordered as a first-tier diagnostic test for a child suspected of having a genetic disorder, rare disease, or condition of unknown origin, including congenital anomalies, global developmental delay, or intellectual disability. It also defines the sequencing service to include the underlying analysis, interpretation, and data report, and it allows sequencing of a first-degree biological relative when needed for the child’s diagnosis or treatment.
The bill would also require state Medicaid plans to pay for whole genome and whole exome sequencing separately rather than bundling the cost into another service payment. In addition to the coverage clarification, it directs the Secretary of Health and Human Services to convene stakeholders, conduct outreach, and publish a report on payment amounts, utilization, health outcomes, and related services. The Comptroller General would also be required to study implementation issues, including access barriers, prior authorization, genetic counselor workforce and reimbursement challenges, and whether Medicaid payment levels align with market costs and Medicare laboratory fee schedules.
If enacted, the bill would amend sections 1905 and 1902 of the Social Security Act and create a new federal Medicaid coverage framework for genomic testing in pediatric cases. It would affect state Medicaid plans by requiring them to recognize these sequencing tests as covered diagnostic services and to make separate payments for them. The bill is set to apply beginning January 1, 2027, giving states and providers time to adjust billing, coverage policies, and administrative processes.
The available context shows no recorded committee debate or votes, so there is no documented partisan or stakeholder sentiment in the provided materials. Based on the bill text, the overall tone appears supportive of expanding access to advanced genetic diagnostics for children, with a strong emphasis on reducing denials and improving awareness among providers, states, and families. The reporting and study provisions suggest an intent to monitor implementation closely rather than simply mandate coverage without oversight.
Potential points of contention include Medicaid costs, state implementation burdens, prior authorization requirements, and whether the bill could increase utilization of expensive genomic tests. The bill itself anticipates these concerns by directing HHS and GAO to examine payment adequacy, administrative barriers, and workforce issues for genetic counselors. Stakeholders most likely to support the bill include pediatric specialists, children’s hospitals, geneticists, rare disease advocates, and families of Medicaid-eligible children, while state Medicaid administrators and managed care organizations may focus on fiscal and operational impacts.
The bill would amend the Social Security Act to add whole genome sequencing and whole exome sequencing as explicitly covered Medicaid diagnostic services for certain children and to require separate reimbursement for those services. It would also impose federal outreach, reporting, and oversight obligations on HHS and the Comptroller General, affecting state Medicaid plan administration, billing practices, prior authorization policies, and access to genetic testing for children eligible for early and periodic screening, diagnostic, and treatment services.
The provided record contains no committee transcript or vote history, so there is no formal recorded sentiment from debate or floor action. The bill’s structure and findings indicate a generally favorable policy posture toward expanding pediatric access to genomic testing, improving awareness, and reducing administrative barriers, while also acknowledging the need to study costs, reimbursement, and implementation challenges.
The main areas of likely contention are cost, reimbursement methodology, and administrative burden. States and Medicaid managed care organizations may be concerned about increased spending, the requirement for separate payment, and the effect of prior authorization rules, while providers and rare disease advocates are likely to favor broader access and fewer denials. The bill specifically flags these issues for study, including whether payment rates align with market costs and whether genetic counselor workforce constraints could limit access.